Although the effects of anti-TNF therapies on circulating insulin and glucose levels in patients with severe chronic inflammation are well established [18, 40], past attempts at restoring insulin sensitivity using non-selective TNF antagonists that block both membrane-bound and solTNF failed in the presence of metabolic syndrome or obesity conditions [17, 41]. Here, TNF is linked to metabolic syndrome.